Identifying Predictors of Peripheral Intravenous Catheter Failure Using a Novel Combination of Clinical and Ultrasonographic Assessments

Amit Bahl (amit.bahl@beaumont.edu)  
Beaumont Hospital

Steven Johnson  
Beaumont Hospital

Nicholas Mielke  
Oakland University William Beaumont School of Medicine

Patrick Karabon  
Oakland University William Beaumont School of Medicine

Research Article

Keywords: Peripheral intravenous access, IV failure, ultrasound, clinical assessment, subcutaneous edema, mechanical irritation, neutrophil to lymphocyte ratio, inflammation, vesicants

DOI: https://doi.org/10.21203/rs.3.rs-283800/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Objective:

Peripheral intravenous catheter (PIVC) failure occurs frequently, but the underlying mechanisms of failure are poorly understood. We aim to identify factors that predict premature PIVC failure.

Methods:

We conducted a single site prospective observational investigation at an academic tertiary care center. Adult emergency department (ED) patients who underwent traditional PIVC placement in the ED and required admission with an anticipated hospital length of stay greater than 48 hours were included. Ongoing daily PIVC assessments included clinical and ultrasonographic evaluations. The primary goal was to identify demographic, clinical, and PIVC related variables that predicted PIVC failure. Univariate and multivariate analyses were employed to identify risk factors for PIVC failure.

Results:

In July and August of 2020, 62 PIVCs were enrolled. PIVC failure occurred in 24 (38.71%) participants. Multivariate logistic regression demonstrated that the presence of subcutaneous edema [AOR 8.29 (1.50, 45.8) p = 0.0153], an above average neutrophil to lymphocyte (N:L) ratio [AOR 4.63 (1.06, 20.3) p = 0.0422], and the administration of an irritant/vesicant [10.3 (1.46, 72.6) p = 0.0.192] were associated with increased likelihood of premature PIVC failure.

Conclusions:

PIVC failure is related to clinical and ultrasonographic variables associated with inflammation: elevated N:L ratio, use of caustic medications, and presence of subcutaneous edema on ultrasound. Reducing inflammation of the vein may lead to better PIVC survival outcomes. Further large-scale randomized controlled trials are needed to validate and build upon the concepts in this study.

Introduction

The placement of peripheral intravenous catheters (PIVC) is the most commonly performed invasive procedure in the acute care clinical setting with over 300 million PIVCs inserted annually in the United States alone.\(^1\)\(^-\)\(^3\) Up to 90% of hospitalized patients require a PIVC for therapy with many patients relying on functional vascular access for the delivery of life-saving fluids and medications.\(^1\) Unfortunately, PIVCs have high failure rates ranging from 36% to 63% leading to significant patient safety and cost implications.\(^2\)\(^-\)\(^4\) Patients may suffer a multitude of sequelae from PIVC failure including extravasation with skin necrosis, catheter associated bloodstream infections, interruption of medical therapies, and longer hospital stays.\(^5\)\(^-\)\(^7\) Further, PIVC failure results in additional invasive procedures to obtain vascular access often requiring multiple needle sticks and reinsertions that may lead to venous depletion leaving
limited or no viable peripheral venous access options. Once venous depletion develops PIVC insertion becomes more difficult and it is estimated that up to 3% of patients require a central venous access device.\textsuperscript{8}

A better understanding of the etiology of PIVC failure is critical to improve patient outcomes. Most of the existing literature highlights the various causes of PIVC failure (phlebitis, infiltration, occlusion) but as presence of these complications generally equates to need for catheter removal, once the complication is externally evident, little can be done to reverse course.\textsuperscript{9} Prevention of these complications requires focusing on the changes beneath the skin that begin soon after PIVC insertion and progress over time.\textsuperscript{10,11} Thus, investigating the anatomical changes at the subcutaneous level after PIVC insertion may unlock the secret to improved survivorship. Some recent exploratory data indicates that PIVC failure is due to ongoing inflammation of the vein.\textsuperscript{12,13} Internally, venous changes can include narrowing of vein wall, wall thickening, and presence of thrombus even in the absence of any clinical signs and symptoms.\textsuperscript{11} The incorporation of venous duplex ultrasonography to the site evaluation provides an objective means to characterize the ongoing changes underneath the skin and may help identify inflammatory variables that lead to PIVC failure.

The goal of this investigation is to create a predictive model for PIVC failure based upon our hypothesis that inflammation is the root cause of the problem. We aim to use demographic, clinical, and sonographic variables to identify risk factors associated with PIVC failure.

**Materials And Methods**

**Study Design, Setting, and Selection of Participants**

This study was a prospective observational investigation of PIVC failure. The study was conducted at a large 1100 bed tertiary care center with an annual ED census of greater than 130,000 visits. The Beaumont Institutional Review Board (IRB) approved this study.

Study investigators recruited a convenience sample of ED patients meeting inclusion criteria. Patients aged at least 18 years with anticipated hospitalization of greater than 48 hours and a PIVC placed using direct visualization and/or palpation in the ED were eligible participants. Patients admitted to the high acuity progressive and intensive care units were specifically targeted to increase the likelihood of meeting the minimum hospital length of stay goal of 48 hours. Patients were excluded if they voluntary withdrew or were cognitively impairment. Additionally, if the PIVC was inserted with ultrasound guidance or if the first sonographic assessment could not be conducted within 24 hours of PIVC placement then the patient was not eligible for enrollment. Informed consent was obtained for all subjects prior to enrollment in the study. All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the Declaration of Helsinki.

**Study Procedure**
After patient enrollment, researchers performed an initial assessment of the patient. Pertinent demographic and clinical data was abstracted from the electronic medical record (EMR) and included age, body mass index, admission blood pressure, admission heart rate, gender, smoking history, pre-existing medical conditions (diabetes, deep vein thrombosis history, clotting disorder, cancer), and use of anticoagulant medications.

PIVC function was confirmed by clinical assessment (per institutional standard), in which a functional PIVC can be flushed without resistance and shows no external signs of unresolvable complication. PIVC complications include pain and/or tenderness, redness, and leaking or swelling around the PIVC site. PIVC failure was defined as failure of functionality based upon the clinical treatment team's impression. Next, the investigator performed a sonographic evaluation of the PIVC and surrounding area using a uniform scanning technique that has been previously described in the literature. Study investigators trained in using ultrasound were responsible for obtaining images. The Mindray M7 Ultrasound Machine with a 14 MHz high frequency linear array transducer was used for all sonographic evaluations. After a small amount of sterile gel was placed on the non-bordered transparent dressing proximal to the PIVC insertion site, the PIVC and surrounding tissue was scanned proximally (towards the heart) 10 cm (length) x 5 cm (width) in short axis extending from the hub of the PIVC. Similar scanning was performed over the same area in the long axis. Appendix A demonstrates scan area. Adequate placement of the PIVC within the vein was confirmed using ultrasound. Gel was wiped off the dressing and skin after the imaging took place.

A series of cine clips (five seconds duration) of the scan area were recorded. All ultrasound images were saved and archived in QPath, a secure and Health Insurance Portability and Accountability Act (HIPPA) compliant storage warehouse for review and interpretation by the Emergency Ultrasound Director. The following measurements were made by post-processing of the original images: catheter-to-vein ratio, length of catheter in vein, angle of insertion, angle of distal tip against vessel wall, vein wall thickness, distance of catheter tip to vessel wall, degree of catheter kinking, and size of thrombus formation (Appendix B).

Investigators performed follow-up ultrasound and clinical assessments on all catheters daily for the life of the PIVC. At each follow-up interval, the researcher documented the time of evaluation and performed a sonographic assessment using the identical method as described above for the initial assessment. These images were also saved and archived similar to the index evaluation.

Clinical staff documents functional status of PIVCs in the EMR as a standard of care measure within our institution. Daily assessment of catheter function was accomplished by reviewing this documentation in the EMR for any notation of catheter failure and complications. If the investigators had any questions or concerns regarding the functionality of the PIVC, clinical staff was brought to the bedside to reassess functionality the PIVC. If the catheter failed or was removed prior to a follow-up assessment, the PIVC failure time, assessment of failure, and reason for line removal was obtained though EMR review and discussion with the nursing staff when possible.
Within 24 hours of PIVC placement, researchers used ultrasound to assess the PIVC site by measuring the diameter of the vein, length of the catheter in the vein, the angle of PIVC insertion, and the angle of the distal tip of the catheter to the vessel wall (Appendix B). After initial assessment of the PIVC, researchers continued to monitor the PIVC and surrounding tissue on a daily basis to follow the progression of the complication. Daily measurements included vein wall thickness, distance of catheter tip to vessel wall, degree of catheter kinking, as well as the assessment of thrombus or subcutaneous edema (Appendix C).

During every ultrasound evaluation, the insertion site was examined by the researcher and assessed using a standardize visual phlebitis scale. The participant was considered symptomatic if they received a score of grade 1 or greater based on a standardized phlebitis scale, which includes the presence of erythema, pain, and/or edema at the access site. All medications administered through each catheter was queried and cross referenced against known irritants and vesicants, as defined by the Infusion Nursing Society. Frequency of administration and dosages were recorded. Beyond vesicants and irritants, the number of overall catheter events were recorded. A catheter event was defined as any instance where fluid was administered through the catheter, including administration of a bolus, initiation of a drip, non-irritant medication administration. Flushing was considered a component of routine care and PIVC maintenance and was not considered an independent event.

Outcome Measures

The primary endpoint was to identify risk factors associated with premature PIVC failure.

Statistical Rationale and Analysis

Continuously measured variables were displayed in terms of mean/average with standard deviation while categorical variables were displayed as frequencies with percentages in parentheses. Univariate, or unadjusted, analysis was performed. Continuous variables were stratified by catheter failure and compared using a Two Samples Independent T-Tests. Categorical variables also were stratified by catheter failure and compared using Chi-Square tests. Odds Ratios (OR) with corresponding 95% Confidence Intervals (95% CI) also were displayed for categorical variables. In addition, univariate logistic regression models were used and results were displayed in terms of Odds Ratios (OR) with corresponding 95% CI and P-Values. Kaplan-Meier Curves were graphically generated to show the difference in time-to-event outcomes in selected characteristics.

Multivariate/adjusted models also were generated as part of this study. Variables included in these models were chosen by all authors based on clinical rationale and the univariate/unadjusted findings. Firth's Penalized Likelihood was employed to mitigate the potential bias caused by the relatively small sample. A multivariate logistic regression model was used. Effect sizes were shown in terms of Adjusted Odds Ratios (AOR) with 95% CI and P-Values for the logistic model.

P-Value < 0.05 indicates a statistically significant finding. All significant findings represent associations as no formal attempts were made to identify cause-and-effect, or causal, relationships. All analysis was
performed in SAS 9.4 (SAS Institute Inc., Cary, NC, USA).

**Results**

In July and August of 2020, 77 patients were consented for the study, of these, 15 participants were excluded. 11 of these patients were lost to follow up (5 PIVCs failed and 7 patients were discharged prior to the first ultrasound evaluation), 3 PIVCs were excluded as two had incomplete PIVC documentation in the chart and one patient voluntarily withdrew from the study. Of the remaining 62 PIVCs, 24 (38.7%) met criteria for premature failure and 38 (61.2%) survived to completion of therapy. The mean catheter dwell time was 76.42 hours (SD = 66.60).

Patient characteristics and comorbidities were similar between the catheters that failed and survived to completion of therapy (all $P \geq 0.05$). Among the 62 patients in the final cohort, 53 had available complete blood count with differential data from admission and were assessed for neutrophil and lymphocyte. The average neutrophil count in failed PIVCs was 10.77 (SD = 4.15), vs 5.41 ($P < 0.0001$) in PIVCs that survived to treatment completion. Similarly, the average Neutrophil to Lymphocyte (N:L) ratio was 12.12 (SD = 8.52) in the failed PIVC group, compared to 5.29 (SD = 4.44) in the group of PIVCs that survived to completion of therapy ($P = 0.0018$) (Table 1).

Our analysis showed a significant association between subcutaneous edema and catheter failure; while 57.14% of PIVC’s that had subcutaneous edema failed, only 14.81% of PIVC’s without subcutaneous edema failed ($P = 0.0020$) (Figure 1A). There is also a significant association between premature catheter failure and the administration of vesicants/irritants ($P = 0.0064$) (Figure 1B). There also are findings linking catheter failure to usage of the PIVC. The number of catheter events that occurred during the life of the catheter in the survival group was 3.39, which was significantly less than the failure group at 5.58 ($P = 0.0011$). In terms of the number of days the catheter is idle, the average percent of days idle for the survival group was 38%, compared to just 6% in the failure group ($P < 0.0001$) (Table 2).

Unadjusted for other factors, logistic regression analysis demonstrated that subcutaneous edema was associated with 6.91-fold greater odds of catheter failure ($P = 0.0020$). At the time of admission, those with an N:L ratio of $\geq 8.1$ demonstrated 6.85-fold greater odds of catheter failure ($P = 0.0029$). Patients with more than one PIVC present throughout their hospital course were associated with greater odds of catheter failure (OR = 6.53; $P = 0.0044$). In regards to IV infusates, the administration of vesicants/irritants was linked to 8.95-fold greater odds of premature catheter failure ($P = 0.0064$) (Table 3).

Multivariate logistic regression analysis, which was adjusted for other factors, demonstrated subcutaneous edema was independently associated with 8.29-fold greater odds of premature catheter failure ($P = 0.0153$). Additionally, those with N:L ratio of $\geq 8.1$ had 4.63-fold greater odds of premature catheter failure ($P = 0.0422$). Furthermore, administration of a vesicant/irritant to the PIVC was associated with 10.3-fold greater odds of premature PIVC failure ($P = 0.0192$) (Table 3).
Discussion

We found that the presence of subcutaneous edema, a N:L ratio of $\geq 8.1$, and administration of vesicants/irritants were predictive of PIVC failure. These results supported our hypothesis that inflammation is a major contributor to poor PIVC survivorship. Our study added to the growing body of literature that has identified subcutaneous edema, a marker of inflammation, as a relevant variable in PIVC outcomes. Further, to our knowledge, this is the first investigation that identifies subcutaneous edema as a major predictor of PIVC failure. Additionally, we discovered that an increased neutrophil to lymphocyte ratio increased the risk of PIVC failure, suggesting further investigation is needed to better understand these mechanisms on a cellular level.

Existing prediction models for PIVC failure are sparse. In one multivariate analysis, traditional inserter-related variables such as catheter diameter and site of insertion were linked to PIVC failure. The authors concluded that smaller catheter diameters and forearm placement were associated with the best PIVC survival rates. As the wrist and hands have the worst outcomes and no catheters in our study were placed in these locations, this variable was not a relevant predictor in our cohort. Additionally, a catheter to vein ratio of less than 0.33 has been identified as a risk factor for catheter failure. In our study over 80% of the catheters were 20-gauge in diameter and the average catheter to vein ratio was 0.36, suggesting that the impact of catheter diameter on PIVC failure was also likely minimal in our cohort. Despite what would appear as optimal PIVC conditions according to prior research, we still noted a high failure rate of 38.7% highlighting the need for further investigation.

Other trials have recently implicated mechanical irritation of the vein wall as a strong predictor of catheter-induced inflammation. In an analysis on the location of catheter tip position within the vein, Murayama et al. found that contact of the tip against the vein wall was associated with subcutaneous edema on ultrasound. Another study in an animal model found that modification of the catheter with the goal of reducing contact against the vein wall led to a 40% reduction in subcutaneous edema. In our study, not only did we identify that subcutaneous edema existed in the majority of our insertions, but we also found that subcutaneous edema on ultrasound was a significant predictor of PIVC failure, a key clinical outcome measure. However, unlike previous investigations, we tracked onset and progression of subcutaneous changes using an innovative methodology inclusive of daily ultrasound site assessments. Serial tracking helped identify that the location of the tip of the catheter was not a static condition, but rather a variable that potentially changed daily. In 44 (71%) cases, the catheter tip to wall distance varied among serial ultrasound evaluations. In 87% of cases, the catheter tip contacted the vein wall at least once during its lifespan illustrating that irritation from the tip likely occurs in more PIVCs than previously reported. It also highlights that PIVC tip position is not a static variable and natural ebbs and flows in the degree of inflammation caused by mobility of the catheter should be considered when seeking solutions to the PIVC failure problem.

We identified that ultrasonographic changes began very early after PIVC insertion.
Indeed, laboratory models have demonstrated that the release of inflammatory and pro-thrombotic markers begins as early as the initial IV needlestick.\textsuperscript{19} We found that thrombosis was a nearly universal occurrence with 87% of PIVCs having some degree of catheter-associated thrombosis. This is likely due to the initial cascade of inflammatory markers that is released during PIVC insertion.\textsuperscript{14} We noted that in many cases, thrombus formation occurred rapidly, with 52% of patients developing thrombosis within 24 hours of PIVC placement. However, not all thrombosis was clinically significant. We noticed that a subset of patients had no progression or change in the ultrasonographic site assessment, while a larger group had significant progression and eventual development of subcutaneous edema. These findings suggest that while initial release of inflammatory and pro-thrombotic markers is likely inevitable, their continued release is a key step in premature PIVC failure. Therefore, to improve PIVC survival methods to reduce continued inflammatory marker release are needed. While reducing continued inflammatory marker release is likely achievable by mechanical modification of the PIVC position, our research also elucidated another potential target to help reduce the rate of PIVC failure.

Cellular models show that significant ongoing inflammatory marker release results in local neutrophil recruitment, activation, and neutrophil extracellular trap (NET) formation. NET formation has recently been implemented in a variety of pathologic, pro-thrombotic, conditions such as stroke, myocardial infarction, and deep venous thrombosis.\textsuperscript{20} Thrombosis in the presence of NETs is resistant to normal mechanisms of clot degradation.\textsuperscript{20} We found that increased neutrophil to lymphocyte N:L ratio as well as a higher circulating neutrophil count was predictive of PIVC failure. In multivariate analysis, we found that N:L ratio of \( \geq 8.1 \) had 4.63-fold greater odds of premature catheter failure. Our data confirms that while thrombus was almost universal, only once significant signs of inflammation were present did premature PIVC failure occur. Therefore, ongoing inflammatory marker release resulting in local neutrophil activation which leads to “inflammatory NET thrombus” is likely a key component of premature catheter failure. Thus, in addition to modifying mechanical PIVC factors to reduce ongoing inflammation, another strategy to increase PIVC survival may be prevention of NET thrombosis formation, rather than simple antithrombogenic coatings that have been recommended previously.

This study took place during the COVID pandemic, thus only a small sample size was obtained due to personal protective equipment limitations and research regulations within the hospital. Given the small sample size, effects of certain variables on PIVC failure may be underestimated, particularly factors with marginal significance. Further, the findings may not be generalized to all settings as the study was conducted at a large academic tertiary care center with a unique population. Additionally, if the PIVC failed or patients were discharged during off hours, the final determination of whether a PIVC was considered a success or failure was based on documentation within the study participant's medical record. In some instances, the researchers found PIVCs with sonographic signs of severe inflammation, but clinical staff was not available to perform bedside functionality assessment of the catheter. It is possible that there may have been a delay in the recognition of PIVC complication and failure in some cases.
This study’s findings demonstrate that the presence of subcutaneous edema, an increasing N:L ratio, and the administration of vesicants/irritants increase the risk of premature PIVC failure. Inflammation plays a key role in precipitating PIVC failure and solutions targeting reduction in inflammation may substantially improve PIVC outcomes. Additional larger, prospective research investigations are needed to validate and build upon these findings.

Declarations

Acknowledgments

S. Matthew Gibson, RN for his input and editing of the manuscript.

Author Contributions

The authors confirm contribution to the paper as follows: study conception and design: AB, NM; data collection: AB, SJ, NM; analysis and interpretation of results: AB, SJ, NM, PK; draft manuscript preparation: AB, SJ, NM, PK. All authors reviewed the results and approved the final version of the manuscript.

Additional Information

The authors declare no competing interests.

References

1. Wallis MC, McGrail M, Webster J, et al. Risk Factors for Peripheral Intravenous Catheter Failure: A Multivariate Analysis of Data from a Randomized Controlled Trial. Infect Control Hosp Epidemiol. 2014;35(1):63-68. doi:10.1086/674398

2. Rickard CM, Marsh N, Webster J, et al. Dressings and securements for the prevention of peripheral intravenous catheter failure in adults (SAVE): a pragmatic, randomised controlled, superiority trial. Lancet. 2018;392(10145):419-430. doi:10.1016/S0140-6736(18)31380-1

3. Helm RE, Klausner JD, Klemperer JD, Flint LM, Huang E. Accepted but Unacceptable: Peripheral IV Catheter Failure. J Infus Nurs. 2015;38(3):189-203. doi:10.1097/NAN.0000000000000100

4. Kache S, Patel S, Chen N-W, Qu L, Bahl A. Doomed peripheral intravenous catheters: Bad Outcomes are similar for emergency department and inpatient placed catheters: A retrospective medical record review. J Vasc Access. November 2020:112972982097425. doi:10.1177/1129729820974259

5. Hawes ML. A Proactive Approach to Combating Venous Depletion in the Hospital Setting. J Infus Nurs. 2007;30(1):33-44. doi:10.1097/00129804-200701000-00006

6. Greig JM. Septic discitis and other complications of peripheral venous cannulation. QJM. 2002;95(6):412-413. doi:10.1093/qjmed/95.6.412
7. Doellman D, Hadaway L, Bowe-Geddes LA, et al. Infiltration and Extravasation. *J Infus Nurs.* 2009;32(4):203-211. doi:10.1097/NAN.0b013e3181aac042

8. Jones RK. Short Peripheral Catheter Quality and Economics. *J Infus Nurs.* 2018;41(6):365-371. doi:10.1097/NAN.0000000000000303

9. Gorski LA, Hadaway L, Hagle ME, et al. Infusion Therapy Standards of Practice, 8th Edition. *J Infus Nurs.* 2021;44(1S):S1-S224. doi:10.1097/NAN.0000000000000396

10. Takahashi T, Murayama R, Abe-Doi M, et al. Preventing peripheral intravenous catheter failure by reducing mechanical irritation. *Sci Rep.* 2020;10(1). doi:10.1038/s41598-019-56873-2

11. Goel D, Smithimdehin A, Yadav B, et al. Ultrasound-detected venous changes associated with peripheral intravenous placement in children. *Br J Nurs.* 2020;29(8):S44-S49. doi:10.12968/bjon.2020.29.8.s44

12. Weiss D, Gefen A, Einav S. Modelling catheter–vein biomechanical interactions during an intravenous procedure. *Comput Methods Biomech Biomed Engin.* 2016;19(3):330-339. doi:10.1080/10255842.2015.1024667

13. Weiss D, Rotman OM, Einav S. Quantitative T2 mapping for detection and quantification of thrombophlebitis in a rabbit model. *J Biomech.* 2017;50:151-157. doi:10.1016/j.jbiomech.2016.11.021

14. Murayama R, Takahashi T, Tanabe H, et al. The relationship between the tip position of an indwelling venous catheter and the subcutaneous edema. *Biosci Trends.* 2015;9(6):414-419. doi:10.5582/bst.2015.01114

15. Gorski LA, Stranz M, Cook LS, et al. Development of an Evidence-Based List of Noncytotoxic Vesicant Medications and Solutions. *J Infus Nurs.* 2017;40(1):26-40. doi:10.1097/NAN.0000000000000202

16. Firth D. Bias Reduction of Maximum Likelihood Estimates. *Biometrika.* 1993;80(1):27-38. doi:10.2307/2336755

17. Tanabe H, Takahashi T, Murayama R, et al. Using ultrasonography for vessel diameter assessment to prevent infiltration. *J Infus Nurs.* 2016;39(2):105-111. doi:10.1097/NAN.0000000000000159

18. Weiss D, Yaakobovitch H, Tal S, Nyska A, Rotman OM. Novel short peripheral catheter design for prevention of thrombophlebitis. *J Thromb Haemost.* 2019;17(1):39-51. doi:10.1111/jth.14350

19. Weiss D, Avraham S, Guttlieb R, et al. Mechanical compression effects on the secretion of VWF and IL-8 by cultured human vein endothelium. *PLoS One.* 2017;12(1):1-16. doi:10.1371/journal.pone.0169752

20. Laridan E, Martinod K, De Meyer S. Neutrophil Extracellular Traps in Arterial and Venous Thrombosis. *Semin Thromb Hemost.* 2019;45(01):086-093. doi:10.1055/s-0038-1677040

**Tables**

**Table 1:** Patient Characteristics, Comorbidities, Vital Signs, Lab Values, & IV Insertion Characteristics
| Patient Characteristics | All PIVCs (n = 62) | Failed (n = 24) | Survived (n = 38) | P-Value |
|-------------------------|-------------------|---------------|----------------|--------|
| Age of Patient (Years)  | Mean (Standard Deviation) | 67.18 (19.25) | 65.79 (18.12) | 68.05 (20.12) | 0.6561 |
| Gender                  | Male              | 32 (51.61%)   | 14 (43.75%)   | 18 (56.25%) | 0.4178 |
|                         | Female            | 30 (48.39%)   | 10 (33.33%)   | 20 (66.67%) | 0.4178 |
| Body Mass Index (BMI) of Patient | Mean (Standard Deviation) | 28.22 (6.82) | 29.22 (7.26) | 27.58 (6.56) | 0.3632 |
| Comorbidities           | History of Smoking | No            | 32 (51.61%)   | 13 (40.63%) | 19 (59.38%) | 0.7588 |
|                         |                   | Yes           | 30 (48.39%)   | 11 (36.67%) | 19 (63.33%) | 0.7588 |
|                         | History of Diabetes | No            | 45 (72.58%)   | 15 (33.33%) | 30 (66.67%) | 0.1735 |
|                         |                   | Yes           | 17 (27.42%)   | 9 (52.94%)  | 8 (47.06%)  | 0.1735 |
|                         | History of Active Cancer | No            | 54 (87.10%)   | 22 (40.74%) | 32 (59.26%) | 0.4820 |
|                         |                   | Yes           | 8 (12.90%)    | 2 (25.00%)  | 6 (75.00%)  | 0.4820 |
|                         | History of Previous DVT | No            | 55 (88.71%)   | 20 (36.36%) | 35 (63.64%) | 0.3243 |
|                         |                   | Yes           | 7 (11.29%)    | 4 (57.14%)  | 3 (42.86%)  | 0.3243 |
|                         | Personal History of Clotting Disorder | No            | 54 (87.10%)   | 19 (35.19%) | 35 (64.81%) | 0.1774 |
|                         |                   | Yes           | 8 (12.90%)    | 5 (62.50%)  | 3 (37.50%)  | 0.1774 |
|                         | Currently on Anticoagulant Medication | No            | 45 (72.58%)   | 18 (40.00%) | 27 (60.00%) | 0.7676 |
|                         |                   | Yes           | 17 (27.42%)   | 6 (35.29%)  | 11 (64.71%) | 0.7676 |
| Vital Signs at Time of Admission | | | | | |
### Systolic Blood Pressure at Admission

|     | Mean (Standard Deviation) |     |     |     |     |
|-----|---------------------------|-----|-----|-----|-----|
|     |                           | 131.95 (20.82) | 126.08 (18.68) | 135.66 (21.47) | 0.0775 |

### Heart Rate at Admission

|     | Mean (Standard Deviation) |     |     |     |     |
|-----|---------------------------|-----|-----|-----|-----|
|     |                           | 84.56 (22.14) | 98.75 (22.01) | 75.61 (17.15) | < 0.0001 |

### Lab Values at Time of Admission

|                  | (n = 53) | (n = 22) | (n = 31) |
|------------------|----------|----------|----------|
| Neutrophils      | Mean (Standard Deviation) | 7.64 (4.36) | 10.77 (4.15) | 5.41 (2.94) | < 0.0001 |
| NL Ratio         | Mean (Standard Deviation) | 8.12 (7.23) | 12.12 (8.52) | 5.29 (4.44) | 0.0018 |
| NL Ratio ≥ 8.5   | Yes | 17 (32.08%) | 12 (70.59%) | 5 (29.41%) | 0.0066 |
|                  | No | 36 (67.92%) | 10 (27.78%) | 26 (72.22%) |
| Lymphocytes      | Mean (Standard Deviation) | 1.31 (0.72) | 1.20 (0.77) | 1.38 (0.69) | 0.3726 |

### IV Insertion Characteristics

#### Laterality of Successful Cannulation

|     |     |     |
|-----|-----|-----|
| Left | 27 (43.55%) | 12 (44.44%) | 15 (55.56%) | 0.4282 |
| Right | 35 (56.45%) | 12 (34.29%) | 23 (65.71%) |

#### Location of IV

|                  |     |
|------------------|-----|
| Antecubital      | 47 (75.81%) | 20 (42.55%) | 27 (57.45%) |
| Forearm          | 15 (24.19%) | 4 (26.67%) | 11 (73.33%) | 0.3180 |

#### >1 IV Placed During Hospital Course

|     |     |     |
|-----|-----|-----|
| No  | 47 (75.81%) | 13 (27.66%) | 34 (72.34%) |
| Yes | 15 (24.19%) | 11 (73.33%) | 4 (26.67%) | 0.0044 |

#### Catheter Gauge (including diameter in mm)

|                  |     |     |     |
|------------------|-----|-----|-----|
| 18: 1.27 mm      | 12 (19.35%) | 5 (41.67%) | 7 (58.33%) | 0.7951 |
| 20: 0.91 mm      | 50 (80.65%) | 19 (38.00%) | 31 (62.00%) |

#### Diameter of Catheter (cm)

|                  | Mean (Standard Deviation) |     |     |     |     |
|------------------|---------------------------|-----|-----|-----|-----|
|                  |                           | 0.10 (0.01) | 0.10 (0.01) | 0.10 (0.01) | 0.8185 |
|                          | Mean (Standard Deviation) | Mean (Standard Deviation) | Mean (Standard Deviation) |  
|-------------------------|---------------------------|---------------------------|---------------------------|
| Vein Diameter (short axis) (cm) | 0.32 (0.13)               | 0.32 (0.14)               | 0.33 (0.13)               | 0.6888                   |
| Catheter-to-vein ratio  | 0.36 (0.15)               | 0.37 (0.16)               | 0.35 (0.15)               | 0.5999                   |
| Length of Catheter in Vein (long axis) (cm) | 1.98 (0.37)               | 1.95 (0.44)               | 2.00 (0.32)               | 0.5949                   |
| Angle of Insertion (long axis) (degrees) | 15.38 (6.47)             | 15.00 (4.58)             | 15.61 (7.43)             | 0.6953                   |
| Angle of Distal Tip Against Vessel Wall (long axis) (degrees) | 6.10 (5.13)              | 5.67 (5.28)              | 6.37 (5.09)              | 0.6039                   |

**Table 2:** Daily IV Characteristics, Clinical Symptoms, Sonographic Findings, IV Infusate Administration, and IV Usage Characteristics
| Daily IV Characteristics | All Lines (n = 62) | Failed (n = 24) | Survived (n = 38) | P-Value |
|--------------------------|-------------------|----------------|------------------|---------|
| Vein Wall Thickness (short axis) (cm) |                  |                |                  |         |
| Mean (Standard Deviation) | 0.04 (0.01)       | 0.04 (0.02)    | 0.05 (0.01)      | 0.5931  |
| Distance of Catheter Tip to Vessel Wall (cm) |                  |                |                  |         |
| Mean (Standard Deviation) | 0.04 (0.04)       | 0.03 (0.03)    | 0.04 (0.05)      | 0.0561  |
| Degree of Catheter Kinking (long axis) (degrees) |                  |                |                  |         |
| Mean (Standard Deviation) | 4.17 (3.31)       | 4.36 (3.28)    | 4.06 (3.37)      | 0.7316  |
| Clinical Symptoms |                  |                |                  |         |
| Phlebitis Scale (0-5) |                  |                |                  |         |
| 0 | 36 (58.06%) | 12 (33.33%) | 24 (66.67%) |         |
| 1 | 20 (32.26%) | 9 (45.00%) | 11 (55.00%) | 0.5963 |
| 2 | 6 (9.68%) | 3 (50.00%) | 3 (50.00%) |         |
| Phlebitis | (n = 54) | (n = 22) | (n = 32) |         |
| Symptomatic | 22 (40.74%) | 11 (50.00%) | 11 (50.00%) | 0.2682 |
| Asymptomatic | 32 (59.26%) | 11 (34.38%) | 21 (65.63%) |         |
| Sonographic Findings |                  |                |                  |         |
| Presence of subcutaneous edema |                  |                |                  |         |
| No | 27 (43.55%) | 4 (14.81%) | 23 (85.19%) |         |
| Yes | 35 (56.45%) | 20 (57.14%) | 15 (42.86%) | 0.0020 |
| Time to Edema | (n = 35) | (n = 20) | (n = 15) |         |
| Mean (Standard Deviation) | 46.92 (52.32) | 39.17 (34.61) | 57.25 (69.44) | 0.3660 |
| < 24 Hours | 8 (22.86%) | 6 (75.00%) | 2 (25.00%) |         |
| 24 - 48 Hours | 18 (51.43%) | 10 (55.56%) | 8 (44.44%) | 0.5333 |
| > 48 Hours | 9 (25.71%) | 4 (44.44%) | 5 (55.56%) |         |
| Presence of Thrombus | (n = 54) | (n = 22) | (n = 32) |         |
| Yes | 40 (74.07%) | 17 (42.50%) | 23 (57.50%) | 0.6941 |
| No | 14 (25.93%) | 5 (35.71%) | 9 (64.29%) |         |
| Time to Thrombus | (n = 54) | (n = 22) | (n = 32) |         |
| Mean (Standard Deviation) | 26.22 (19.88) | 23.57 (14.94) | 28.05 (22.71) | 0.3862 |
|--------------------------|----------------|----------------|----------------|--------|
| < 24 Hours               | 28 (51.85%)    | 12 (42.86%)    | 16 (57.14%)    |        |
| 24 Hours +               | 26 (48.15%)    | 10 (38.46%)    | 16 (61.54%)    | 0.7535 |

**IV Infusate Administration**

IV fluid bolus or continuous drip administered

|       | Yes     | No       |
|-------|---------|----------|
| Mean  | 49 (79.03%) | 13 (20.97%) |
| SD    | 21 (42.86%) | 3 (23.08%)  |
| < 24 Hours | 28 (57.14%) | 10 (76.92%) |
| 24 Hours + | 26 (48.15%) | 10 (76.92%) |

**IV Medication Administration**

|       | No       | Yes      |
|-------|----------|----------|
| Mean  | 11 (17.74%) | 51 (82.26%) |
| SD    | 1 (9.09%)  | 23 (45.10%) |
| < 24 Hours | 10 (90.91%) | 28 (54.90%) |
| 24 Hours + | 16 (61.54%) | 36 (70.59%) |

**IV Vesicant/Irritant Administration**

|       | No       | Yes      |
|-------|----------|----------|
| Mean  | 11 (17.74%) | 51 (82.26%) |
| SD    | 9 (81.82%)  | 15 (29.41%) |
| < 24 Hours | 2 (18.18%)  | 36 (70.59%) |
| 24 Hours + | 10 (90.91%) | 28 (54.90%) |

**IV Usage Characteristics**

**Catheter Dwell Time (Hours)**

| Mean (Standard Deviation) | 76.42 (66.60) | 66.85 (44.34) | 82.47 (77.42) | 0.3171 |

**Number of Catheter Events**

| Mean (Standard Deviation) | 4.24 (2.65) | 5.58 (2.41) | 3.39 (2.47) | 0.0011 |

**Percent of Days Idle (%)**

| Mean (Standard Deviation) | 26% (31%) | 6% (17%) | 38% (32%) | < 0.0001 |

**Table 3: Univariate and Multivariate Analysis**
|                                    | Univariate | Multivariate |
|------------------------------------|------------|--------------|
|                                    | OR (95% CI)| P-Value      |
|                                    | AOR (95% CI)| P-Value      |
| **Patient Characteristics**        |            |              |
| Gender                             |            |              |
| Male                               | Reference Group | 0.65 (0.23, 1.83) | 0.4178 |
| Female                             | 0.65 (0.23, 1.83) | 0.4178 |
| **Comorbidities**                  |            |              |
| History of Smoking                 |            |              |
| No                                 | Reference Group | 0.85 (0.31, 2.37) | 0.7588 |
| Yes                                | 0.85 (0.31, 2.37) | 0.7588 |
| History of Diabetes                |            |              |
| No                                 | Reference Group | 2.20 (0.71, 6.85) | 0.1735 |
| Yes                                | 2.20 (0.71, 6.85) | 0.1735 |
| History of Active Cancer           |            |              |
| No                                 | Reference Group | 0.56 (0.11, 2.86) | 0.4820 |
| Yes                                | 0.56 (0.11, 2.86) | 0.4820 |
| History of Previous DVT            |            |              |
| No                                 | Reference Group | 2.23 (0.45, 10.9) | 0.3243 |
| Yes                                | 2.23 (0.45, 10.9) | 0.3243 |
| Personal History of Clotting Disorder |          |              |
| No                                 | Reference Group | 2.86 (0.62, 13.2) | 0.1774 |
| Yes                                | 2.86 (0.62, 13.2) | 0.1774 |
| Currently on Anticoagulant Medication |          |              |
| No                                 | Reference Group | 0.84 (0.27, 2.67) | 0.7676 |
| Yes                                | 0.84 (0.27, 2.67) | 0.7676 |
| **Lab Values at Time of Admission**|            |              |
| NL Ratio &gt; 8.1                  |            |              |
| Yes                                | 6.85 (1.93, 24.3) | 0.0029 | 4.63 (1.06, 20.3) | 0.0422 |
| No                                 | Reference Group | Reference Group | Reference Group |
| N:L Ratio | 1.19 (1.05, 1.34) | 0.0052 |
|-----------|------------------|--------|

**IV Insertion Characteristics**

**Laterality of Successful Cannulation**

|          |                  |        |
|----------|------------------|--------|
| Left     | 1.52 (0.54, 4.25) | 0.4282 |
| Right    | Reference Group  |        |

**Location of IV**

|          |                  |        |
|----------|------------------|--------|
| Antecubital | Reference Group       |        |
| Forearm  | 0.53 (0.15, 1.86)  | 0.3180 |

**>1 IV Placed During Hospital Course**

|          |                  |        |
|----------|------------------|--------|
| No       | Reference Group  |        |
| Yes      | 6.53 (1.79, 23.8) | 0.0044 |

**Catheter Gauge (including diameter in mm)**

|          |                  |        |
|----------|------------------|--------|
| 18: 1.27 mm | 1.19 (0.33, 4.26)  | 0.7951 |
| 20: 0.91 mm | Reference Group       |        |

**Catheter-to-Vein Ratio**

|          |                  |        |
|----------|------------------|--------|
| Ratio ≥ 33% | 1.23 (0.44, 3.42)  | 0.6935 |
| Ratio < 33% | Reference Group       | 0.91 (0.21, 3.97)  | 0.8996 |

**Daily IV Characteristics**

**Distance Catheter Tip to Vein Wall**

|          |                  |        |
|----------|------------------|--------|
| 0 only   | Reference Group  | Reference Group |
| 0 and > 0 | 0.80 (0.25, 2.50)  | 0.6962 |
| > 0 only | 0.48 (0.08, 2.89)  | 0.4187 |
|          | 1.13 (0.09, 14.2) | 0.9267 |

**Clinical Symptoms**

**Phlebitis Scale (0-5)**

|          |                  |        |
|----------|------------------|--------|
| 0        | Reference Group  |        |
| 1        | 1.62 (0.53, 4.96) | 0.3987 |
| 2        | 1.96 (0.34, 11.2) | 0.4495 |

**Phlebitis**

|          |                  |        |
|----------|------------------|--------|
| Symptomatic | 1.87 (0.62, 5.66)  | 0.2682 |
| Asymptomatic | Reference Group |
|--------------|-----------------|

**Sonographic Findings**

| Subcutaneous Edema |  |  |  |
|---------------------|-----------------|-----------------|-----------------|
| Yes                 | 6.91 (2.03, 23.5) | 0.0020          | 8.29 (1.50, 45.8) | 0.0153          |
| No                  | Reference Group  | Reference Group | Reference Group  | Reference Group |

**Time to Edema**

|  |  |  |
|-----------------|-----------------|-----------------|
| < 24 Hours      | Reference Group | Reference Group |
| 24 - 48 Hours   | 0.48 (0.08, 2.89) | 0.4190          |
| > 48 Hours      | 0.32 (0.04, 2.40) | 0.2642          |

**Presence of Thrombus**

|  |  |  |
|-----------------|-----------------|-----------------|
| Yes             | 1.29 (0.37, 4.51) | 0.6941          |
| No              | Reference Group  | Reference Group |

**Time to Thrombus**

|  |  |  |
|-----------------|-----------------|-----------------|
| < 24 Hours      | Reference Group | Reference Group |
| 24 Hours +      | 0.84 (0.28, 2.49) | 0.7535          |

**IV Infusate Administration**

**IV Fluid Bolus or Continuous Drip Administered**

|  |  |  |
|-----------------|-----------------|-----------------|
| Yes             | 2.26 (0.57, 8.97) | 0.2450          |
| No              | Reference Group  | Reference Group |

**IV Medication Administered**

|  |  |  |
|-----------------|-----------------|-----------------|
| No              | Reference Group  | Reference Group |
| Yes             | 5.77 (0.89, 37.5) | 0.0661          |

**Vesicant/Irritant Administered**

|  |  |  |  |
|-----------------|-----------------|-----------------|-----------------|
| Yes             | 8.95 (1.85, 43.2) | 0.0064          | 10.3 (1.46, 72.6) | 0.0192          |
| No              | Reference Group  | Reference Group | Reference Group  | Reference Group |